Professor of Chemistry; Interim Chair of the Chemistry Department, University of South Florida
Professor James Leahy has extensive experience in researching to discover new drug candidates with fully optimized pharmacokinetic and pharmacodynamics parameters, having advanced more than a dozen compounds into human clinical trials including the discovery of Cometriq/Cabozantinib/XL184. Toward this end, the Leahy group is actively engaged in collaborative research efforts aimed at the synthesis and optimization of small molecule leads in a number of therapeutic areas such as infectious diseases and neurological disorders as well as the pursuit of novel synthetic methodology.
Strides in medicine have contributed to a dramatic increase in life expectancy over the last century. Diseases like HIV and cervical cancer that were essentially death sentences as recently as 30 years ago can now be...